Xiangyu Guo

Shenyang, 110042, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

The novel oleanolic acid derivative ZQL-4c modulates trastuzumab resistance in HER2+ breast cancer by inhibiting SCD-mediated lipid metabolism disorders.

The novel oleanolic acid derivative ZQL-4c modulates trastuzumab resistance in HER2+ breast cancer by inhibiting SCD-mediated lipid metabolism disorders.

Journal: Cancer cell international

Published: April 02, 2026

ZQL-4c exerts anti-tumor effects by specifically targeting SCD1 in triple-negative breast cancer both in vitro and in vivo.

ZQL-4c exerts anti-tumor effects by specifically targeting SCD1 in triple-negative breast cancer both in vitro and in vivo.

Journal: Chinese medical journal

Published: December 01, 2024

Pyrotinib and Nab-Paclitaxel in HER2-Positive Breast Cancer (PANHER Trial): A Prospective, Single-Arm, Phase II Trial.

Pyrotinib and Nab-Paclitaxel in HER2-Positive Breast Cancer (PANHER Trial): A Prospective, Single-Arm, Phase II Trial.

Journal: Cancer science

Published: November 21, 2024

Real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab.

Real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab.

Journal: Frontiers in oncology

Published: September 14, 2024

Corrigendum to: Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells.

Corrigendum to: Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells.

Journal: Anti-cancer agents in medicinal chemistry

Published: February 20, 2024

SZC010 suppresses breast cancer development by regulating the PI3K/Akt/NF-κB signaling pathway.

SZC010 suppresses breast cancer development by regulating the PI3K/Akt/NF-κB signaling pathway.

Journal: Chinese clinical oncology

Published: January 23, 2024

Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells.

Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells.

Journal: Anti-cancer agents in medicinal chemistry

Published: November 25, 2022

N-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-methylene-3-oxo-olean-12-en-28-amide Induces Apoptosis in Human Breast Cancer Cells by Stimulating Oxidative Stress and Inhibiting the Notch-Akt Signaling Pathway.

N-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-methylene-3-oxo-olean-12-en-28-amide Induces Apoptosis in Human Breast Cancer Cells by Stimulating Oxidative Stress and Inhibiting the Notch-Akt Signaling Pathway.

Journal: Oxidative medicine and cellular longevity

Published: March 03, 2022

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67.

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67.

Journal: OncoTargets and therapy

Published: May 03, 2018

Glycogenolysis in Acquired Glioma Resistance to Temozolomide: A Role for the [Ca2+]i-dependent Activation of Na,K-ATPase/ERK1/2 Signaling.

Glycogenolysis in Acquired Glioma Resistance to Temozolomide: A Role for the [Ca2+]i-dependent Activation of Na,K-ATPase/ERK1/2 Signaling.

Journal: Frontiers in pharmacology

Published: May 03, 2018

Correlation between hormone receptor status and depressive symptoms in patients with metastatic breast cancer.

Correlation between hormone receptor status and depressive symptoms in patients with metastatic breast cancer.

Journal: Oncotarget

Published: September 30, 2016

Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer.

Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer.

Journal: Oncology letters

Published: December 09, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026